 immun function anti-htlv-i/ii statu intraven drug user methadon purpos studi object effect long-term methadon use human t-cell leukemia viru htlv II seroposit distribut lymphocyt subset lymphocyt function vitro intraven drug user human immunodefici viru type patient method intraven drug user methadon mainten therapi veteran administr drug abus treatment center subject age- sex-match control subject drug htlv serostatu repetit enzyme-link immunosorb assay immunoblot lymphocyt subset two-color flow cytometri lymphocyt function prolif respons plant mitogen natur killer NK cell-medi cytotox tumor cell target result signific differ lymphocyt phenotyp methadone-tr group elev t-cell helper subset cell suppressor/cytotox lymphocyt suppressor/cytotox cell cell total lymphocyt function methadon group poor respons mitogen phytohemagglutinin cultur nk-cell cytotox methadon group none immunolog differ attribut htlv serostatu conclus immun abnorm signific degre immun impair exist methadone-tr intraven drug user abnorm presenc retrovirus studi group signific differ immun function htlv-seroposit patient htlv-seroneg subject methadon